Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Wegovy will be available in five dose strengths in India, with 0.25 mg, 0.5 mg and 1 mg versions priced at 4,336.25 rupees ($50.71), the company said. The monthly cost would be 17,345 rupees ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...